Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig + Docetaxel vs Docetaxel in mCRPC
NCT07225946Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Radiographic Progression-Free Survival. Started Dec 2025; status: recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07225946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225946.